Company Profile
Vaxart Stock Price, News & Catalysts
- Ticker:
- VXRT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.49 USD (-9.11%)
Close
Last updated: August 17, 2026
—
Market cap
Why the stock is moving
As of Aug 17, 2026, VXRT closed down 9.11% at $0.4940. No new same-company headline was identified in the current news window.
Company overview
Oral Vaccine Platform
Vaxart is a clinical-stage biotechnology company developing recombinant vaccines delivered as pills. Its platform is designed to eliminate injections and enable products that can be stored and shipped without refrigeration.
Mucosal Immunization Approach
The delivery technology combines an adenoviral vector with a TLR3 agonist to stimulate immune responses at mucosal surfaces. Vaxart aims to create oral alternatives to existing injectable vaccines and vaccines for indications without established products.
COVID-19 Program
The lead Phase 2b program compares Vaxart's oral COVID-19 vaccine with an approved mRNA vaccine. A 400-participant sentinel cohort assessed safety before analysis of the approximately 5,000-participant main cohort.
Broader Vaccine Pipeline
Additional development programs target norovirus and influenza, while a therapeutic HPV vaccine represents the platform's first immuno-oncology application.
Future catalysts
- Topline efficacy and safety results from the complete Phase 2b COVID-19 study in the first half of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Vaxart (VXRT)?
Vaxart (VXRT) most recently closed at 0.49 USD, a -9.11% move versus the previous session.
What does Vaxart do?
Oral Vaccine Platform Vaxart is a clinical-stage biotechnology company developing recombinant vaccines delivered as pills. Its platform is designed to eliminate injections and enable products that can be stored and shipped without refrigeration. Mucosal Immunization Approach The delivery technology combines an adenoviral vector with a TLR3 agonist to...
On which exchange is VXRT stock listed?
Vaxart (VXRT) is associated with NASDAQ, United States, Biopharma.
What is COVID-19?
Topline efficacy and safety results from the complete Phase 2b COVID-19 study in the first half of 2027.
Which conditions is Vaxart targeting with COVID-19?
Vaxart is associated with oncology based on its company overview and current catalyst commentary.
How does Vaxart describe recent progress with COVID-19?
Topline efficacy and safety results from the complete Phase 2b COVID-19 study in the first half of 2027.
What is Oral?
Oral Vaccine Platform Vaxart is a clinical-stage biotechnology company developing recombinant vaccines delivered as pills.
What should investors watch for with Oral?
Topline efficacy and safety results from the complete Phase 2b COVID-19 study in the first half of 2027.